Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- PDK 70S6K 70S6 p70S6 anti-body p-70
- Product Overview:
p70 Ribosomal S6 kinase (p70S6K) is serine/threonine kinase of the S6K family.{60964} It is composed of an N-terminal domain, a kinase domain, and a C-terminal domain and has several phosphorylation sites. There are three isoforms of p70S6K with p70S6K1 and p70S6K2 generated by alternative translation initiation sites and p70S6K3 generated via alternative splicing. p70S6K localizes to the cytoplasm and is activated in response to insulin and growth factor signaling, as well as to amino acids and glucose metabolism.{60965,60964} It is activated in a process requiring phosphorylation of three or four serine residues in the C-terminal domain, depending on the isoform, which induces a conformational change that allows two threonine residues to be phosphorylated by mammalian target of rapamycin (mTOR) and 3-phosphoinositide-dependent protein kinase 1 (PDK1).{60964,60966} Active p70S6K phosphorylates the 40S ribosomal subunit ribosomal protein S6 (RSK), leading to protein synthesis and cell cycle progression.{60965,60964} p70S6K also targets proteins involved in other processes, including cell growth and motility, adipocyte differentiation, and synaptic plasticity.{60966} Expression of RPS6KB1, the gene encoding p70S6K1, is increased in visceral adipose tissue from obese patients.{60967} Cayman’s p70S6K (N-Term) Rabbit Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.